KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Common Equity (2017 - 2025)

Twist Bioscience (TWST) has disclosed Common Equity for 7 consecutive years, with $657.6 million as the latest value for Q2 2023.

  • On a quarterly basis, Common Equity fell 19.88% to $657.6 million in Q2 2023 year-over-year; TTM through Jun 2023 was $657.6 million, a 19.88% decrease, with the full-year FY2022 number at $789.4 million, up 35.91% from a year prior.
  • Common Equity was $657.6 million for Q2 2023 at Twist Bioscience, down from $703.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $863.4 million in Q1 2022 to a low of $103.1 million in Q4 2019.
  • A 5-year average of $508.2 million and a median of $612.3 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: fell 25.62% in 2019, then skyrocketed 518.88% in 2020.
  • Twist Bioscience's Common Equity stood at $103.1 million in 2019, then surged by 518.88% to $638.0 million in 2020, then dropped by 1.85% to $626.2 million in 2021, then grew by 19.19% to $746.3 million in 2022, then fell by 11.89% to $657.6 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Common Equity are $657.6 million (Q2 2023), $703.9 million (Q1 2023), and $746.3 million (Q4 2022).